Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo

Mark A. Little, C. Lucy Smyth, Rashmi Yadav, Lyn Ambrose, H. Terence Cook, Sussan Nourshargh, and Charles D. Pusey

Systemic small vessel vasculitis is associated with antineutrophil cytoplasm antibodies (ANCAs). While there is mounting in vitro evidence to suggest that ANCAs are capable of enhancing leukocyte-endothelial interactions, no in vivo evidence for this has been provided. In this study a novel rat model of ANCA-associated experimental autoimmune vasculitis (EAV), induced by immunization with human myeloperoxidase (MPO), was used to analyze directly the potential effect of ANCAs on leukocyte-venular wall interactions in vivo as observed by intravital microscopy. These rats developed anti-MPO antibodies directed against rat leukocytes, showed pathologic evidence of small vessel vasculitis, and had enhanced leukocyte adhesion and transmigration in response to the chemokine Groα (CXCL1 [CXC ligand 1]). Passive transfer of immunoglobulin from rats with EAV to naive rats conferred enhanced adhesion and transmigration responses in the recipients. Furthermore, rats with EAV and recipients of ANCA-positive immunoglobulin developed extensive microvascular injury, as manifested by mesenteric hemorrhage, in response to CXCL1. This study provides the first direct in vivo evidence for the ability of ANCAs to enhance leukocyte-endothelial interactions and cause microvascular hemorrhage, thereby providing a mechanism by which ANCAs could exert pathogenic effects in systemic vasculitis. (Blood. 2005;106:2050-2058)

© 2005 by The American Society of Hematology

Introduction

Systemic small vessel vasculitis (SVV) results in rapidly progressive glomerulonephritis and lung hemorrhage in humans and is usually fatal if untreated.1 It is characterized by microvascular inflammation and necrosis in a variety of organs. The 2 organs that are most extensively injured in this manner are the kidney, through the development of pauci-immune crescentic glomerulonephritis, and the lung, with consequent alveolar hemorrhage. The association between antineutrophil cytoplasm antibodies (ANCAs) and SVV, initially described in the 1980s,2 has attracted considerable interest over the past decade. These autoantibodies are principally directed against myeloperoxidase (MPO) and proteinase-3.3,4 At first, ANCAs were regarded only as clinical markers of disease activity, but it is now apparent that they have direct biologic effects on neutrophils5,6 and monocytes.7 The binding of ANCAs to antigen expressed on the leukocyte cell surface following cytokine priming is followed by the activation of an array of intracellular signaling pathways,8 with resultant degranulation and dysregulated apoptosis.9 Granulocyte infiltration and fibrinoid necrosis of the vessel wall are the pathologic hallmarks of SVV. For this reason, investigative efforts have focused on the influence that ANCAs have on the interaction between leukocytes and the vascular endothelium, specifically with reference to the inflammatory cascade of leukocyte rolling, adhesion, and transmigration. In this context, in vitro studies using flow chamber models have shown that ANCAs can cause rolling neutrophils to arrest on platelet monolayers10 and to promote firm adhesion and migration of rolling neutrophils on endothelial cells.11,12 Despite growing in vitro evidence implicating ANCAs as an inducer of leukocyte-endothelial cell interactions, there has been no evidence to date demonstrating such an effect of these antibodies in vivo. The ability of ANCAs to induce systemic small vessel vasculitis and crescentic glomerulonephritis, however, has been demonstrated by transfer of anti-MPO antibodies in a mouse model of vasculitis.13 Crescent formation in these animals occurred secondary to fibrinoid necrosis of the glomerular tuft, which was induced by necrosis and occlusion of glomerular capillaries.

To investigate the mechanisms involved in the initiation of inflammatory microvascular injury, we have used a rat model of ANCA-associated SVV (AASV) that mimics the human condition, developed in our laboratory.14 In this model, experimental autoimmune vasculitis (EAV), Wistar-Kyoto (WKY) rats, immunized with purified human myeloperoxidase (hMPO) in complete Freund adjuvant (CFA), develop high titers of ANCAs, accompanied by pauci-immune crescentic glomerulonephritis, and lung hemorrhage. Because the aim of our study was to investigate the hypothesis that ANCAs are capable of promoting leukocyte-endothelial interactions in vivo, leukocyte responses within the mesenteric vascular bed of immunized rats were directly investigated using intravital microscopy. The findings demonstrate...
increased leukocyte firm adhesion and transmigration, as induced by locally administered CXC ligand 1 (CXCL-1; a rat homologue of interleukin 8 [IL-8]), in rats immunized with hMPO, and in naive rats following passive transfer of ANCs from rats with EAV. This was accompanied by microvascular injury, as shown by mesenteric hemorrhage in response to CXCL-1. Collectively, these results provide the first direct in vivo evidence that ANCs can cause enhanced leukocyte-endothelial interactions and support the concept that ANCs are pathogenic.

Materials and methods

Animals

WKY/NCi1BR rats were purchased from Charles River (Margate, United Kingdom). All animal studies were performed according to the directives of the United Kingdom Home Office Animals (Scientific Procedures) Act, United Kingdom (1986).

Immunization protocol and characterization of EAV phenotype

Rats (130-180 g) were immunized intramuscularly with hMPO (400, 800, and 1600 μg/kg; Calbiochem, Merck Biosciences, Nottingham, United Kingdom; n = 13, 11, and 4, respectively) or human serum albumin (HSA; Sigma-Aldridge, Gillingham, United Kingdom; n = 19) in an equal volume of CFA. Hematuria was assessed with dipstick (Bayer Multistix, Berkshire, United Kingdom) and albuminuria with enzyme-linked immunosorbent assay (ELISA; Nephrat ELISA kit; Exocell, Philadelphia, PA). Anti-hMPO antibody levels in serum were measured by ELISA. Briefly, 96-well plates were coated overnight with hMPO (2 μg/mL) in carbonate buffer. Wells were then incubated with dilutions of serum samples in triplicate for 60 minutes at 37°C, washed, and incubated with anti-rat immunoglobulin G (IgG) alkaline phosphatase conjugate (Sigma) for 45 minutes at 37°C. Binding was detected with p-nitrophenylphosphate (p-NPP; Sigma) and read at 405 nm.

Following intravital microscopy, rats were killed, and organs were fixed in formalin (for histologic analysis), snap-frozen in 2-oxacalcitriol (OCT; Miles, Elkhart, IN) (for immunofluorescence staining), and fixed in glutaraldehyde for analysis by electron microscopy. Glomerular crescent percentage was quantified blindly in 100 random glomeruli on each periodic acid Schiff-stained section. Images were captured with an Olympus BX40 microscope (Olympus Optical, London, United Kingdom) and a Photonic Science Color Coolview camera (Photonic Science, East Sussex, United Kingdom). Direct immunofluorescence staining for glomerular IgG deposition was performed on 3-μm frozen sections after fixation in acetone for 10 minutes. Following washing in phosphate-buffered saline PBS, nonspecific binding was blocked by incubation with 20% normal rabbit serum, and sections were then incubated with fluorescein isothiocyanate (FITC)–conjugated anti–rat IgG (Sigma) for 60 minutes. To control for the thickness of the section, images were captured digitally using a laser scanning confocal microscope and Pascal LSM software (LSM5 Pascal; Zeiss, Jena, Germany).

Ig preparation

Ig from pooled rat sera of all actively immunized animals was prepared by 45% ammonium sulfate precipitation. Final Ig preparations had endotoxin levels of less than 5 EU/mL, as measured by Limulus Amebocyte Lysate testing (Bio-Whittaker, Walkersville, MD). All Ig preparations were ultracentrifuged (10^6 g for 30 minutes), and the presence of anti-hMPO antibodies in preparations from rats with EAV was confirmed using ELISA.

Intravital microscopy

Intravital microscopy on rat mesentery was performed as described previously. Briefly, control (n = 18) or EAV (n = 20) rats were anesthetized with intravenous sodium pentobarbitone, without the operator’s knowledge of the immunization status of the rat, and maintained at 37°C on a heated microscope stage. Following midline abdominal incision, the mesentery adjoining the terminal ileum was carefully arranged over a glass window on the stage and superfused with Tyrode balanced salt solution. Baseline quantification of leukocyte rolling, firm adhesion, and transmigration was performed using a fixed stage upright microscope with water immersion objectives (Axioscope; Zeiss). To investigate the effect of recombinant rat CXCL1 (PeproTech, London, United Kingdom), the chemokine was continuously applied topically to the mesentery in the superfusion buffer (final concentration 3 X 10^-7 M), and leukocyte responses were quantified at regular intervals. In experiments investigating passive transfer of ANCs, nonimmunized rats were injected in a blinded fashion with ANCA-containing (n = 9) or control (n = 8) Ig (20 mg/kg intravenously).

In animals that developed extensive hemorrhage, each vessel segment (all of which had been chosen randomly before the addition of a stimulus) was assessed for the presence or absence of hemorrhage at each time point. The number of hemorrhagic venular segments was then expressed as a percentage of the total number of vessel segments observed. This quantification procedure was, however, insensitive for accurate recording of responses in rats with minor degrees of hemorrhage, as seen in the passive transfer experiments. In these, hemorrhage at the vessel segments chosen at the beginning of the experiment was infrequent. In these cases hemorrhage was quantified using a global visual-analog score, defined in dose-finding experiments as 0 = no hemorrhage, 1 = a single focus, 2 = 2 to 5 foci, 3 = 6 to 10 foci, 4 = more than 10 foci with macroscopic petechiae visible, and 5 = widespread hemorrhage with extensive microvascular occlusion. The experiments also typically involved measurement of peripheral differential leukocyte counts, blood pressure, and red blood cell (RBC) velocity; as previously detailed.

Assessment of anti-hMPO crossreactivity with neutrophils from WKY rats

Binding of anti-hMPO antibodies to WKY rat neutrophils was demonstrated by indirect immunofluorescence staining, by flow cytometry, and by Western blotting of leukocyte lysates. With respect to fluorescence staining, neutrophil-rich leukocyte suspensions were prepared from healthy human volunteers and nonimmunized WKY rats by discontinuous density centrifugation. Smears were air-dried and fixed in 95% ethanol before incubation with serum (1:20 in PBS) from EAV (n = 13) or control (n = 10) rats, or plasma (1:20 in PBS) from anti-MPO antibody-positive patients (microscopic polyangiitis, n = 5) or anti-MPO-negative controls (IgA nephropathy, n = 2; antibody-mediated transplant rejection, n = 1). In addition, staining following serial dilution of selected sera to 1:320 was performed. Binding of antibodies was detected using appropriate Alexa Fluor 568–conjugated anti–rat/human IgG antibodies (Molecular Probes, Eugene, OR). Samples were observed using a laser scanning confocal microscope (LSM5 Pascal; Zeiss) with the aid of Pascal LSM software. Fluorescence intensity was quantified using Image-Pro plus software (v3.0; Media Cybernetics, Silver Spring, MD).

For flow cytometry, mixed leukocyte preparations from WKY rats and healthy human volunteers were prepared by sedimentation of red cells using 2.5% Dextran T-500 (Amer sham Biosciences, Chalfont, United Kingdom) with permeabilization of cell samples with Saponin (0.1% in PBS). Surface and intracellular antigen expression was detected with Ig preparations from EAV or control rats (100 μg/mL in PBS/20% rabbit serum) and a FITC–conjugated rabbit anti–rat IgG (Sigma). In selected experiments granulocytes were distinguished by double staining with phycoerythrin (PE)–conjugated HIS48 IgM (Santa Cruz Biotechnology, Santa Cruz, CA). The samples were acquired on a FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Binding of EAV Ig relative to control Ig was expressed as mean ratio of mean fluorescence intensity (RFI).

For Western blot analysis, mixed leukocytes were prepared as for flow cytometry, lysed, and run on sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). Briefly, after lysing residual RBCs with ice-cold NH4Cl lysis solution, the leukocyte pellet was suspended in lysis buffer (1% Triton X-100, 10 mM Tris [tris(hydroxymethyl)aminomethane], 5 mM EDTA [ethylenediaminetetraacetic acid], 50 mM NaCl, 30 mM Na2O–P2, 50 mM NaF, 100 mM Na2VO4, pH 7.6) containing protease
inhibitors (Sigma) and incubated on ice for 20 minutes. The samples were centrifuged at 14,000g for 20 minutes at 4°C, and nondenaturing SDS-PAGE was performed on the lysate supernatant with a Phast-gel system using 7.5% agarose gels (Amersham Pharmacia Biotech, Uppsala, Sweden). The purified hMPO (50 μg/mL) used to induce EAV and lysates of human polymorphonuclear leukocytes (PMNs) purified over Percoll were used as positive controls. Samples were transferred to nitrocellulose membranes and incubated with primary antibodies (Ig preparations from rats with EAV and control rats), followed by incubation with appropriate anti-rat IgG alkaline phosphatase conjugates, with all incubations being for 60 minutes. Binding was detected using BCIP/NBT (5-bromo-4-chloro-3-indolyl-phosphate, 4-nitroblue tetrazolium chloride) alkaline phosphatase substrate (Sigma).

**Statistical analysis**

Normally distributed data are expressed as the mean plus or minus SEM, and non-normal data are expressed as median and interquartile range (IQR). Baseline variables were compared using Student t test, and urinary albumin excretion rate and hemorrhage at 90 minutes was analyzed with the Mann-Whitney test. Intravital microscopy adhesion and transmigration data were analyzed using 2-way analysis of variance (ANOVA), considering time and treatment group as independent variables. Values at individual time points were compared using Bonferroni post hoc tests.

**Results**

**Immunization of WKY rats with hMPO induces anti-hMPO antibodies that bind to WKY rat neutrophils**

To assess the effect of circulating ANCA on microvascular leukocyte-endothelial responses, WKY rats were immunized with hMPO (EAV group) or HSA (control group) in CFA. As there were no differences in any of the outcome variables studied between the hMPO (EAV group) or HSA (control group) in CFA. As there were no differences in any of the outcome variables studied between the hMPO (EAV group) or HSA (control group). The purified hMPO (50 μg/mL) used to induce EAV and lysates of human polymorphonuclear leukocytes (PMNs) purified over Percoll were used as positive controls. Samples were transferred to nitrocellulose membranes and incubated with primary antibodies (Ig preparations from rats with EAV and control rats), followed by incubation with appropriate anti-rat IgG alkaline phosphatase conjugates, with all incubations being for 60 minutes. Binding was detected using BCIP/NBT (5-bromo-4-chloro-3-indolyl-phosphate, 4-nitroblue tetrazolium chloride) alkaline phosphatase substrate (Sigma).

**Immunization of WKY rats with hMPO induces pauci-immune crescentic glomerulonephritis and pulmonary hemorrhage**

Gross examination of lungs and kidney revealed petechiae over the lung surface, and occasional petechiae on the renal surface in rats with EAV, but not in control rats. Prominent macroscopic lung hemorrhage was evident in 41% of rats immunized with hMPO. In all of these, there was histologic evidence of lung vasculitis, with perivascular leukocyte cuffing, occasional vascular occlusion, and alveolar hemorrhage (Figure 2). In 79% of hMPO-immunized animals, but none of the control animals, focal proliferative glomerulonephritis with fibrinoid necrosis was evident (Figure 2). In 78% of these (61% of all hMPO-immunized rats), crescent formation was present (Figure 2). This was focal, with adjacent areas of normal renal tissue, and often associated with foci of tubulo-interstitial nephritis. Immunofluorescence examination of renal sections revealed occasional scanty deposits of IgG. The amount of deposits was above the background level seen with sections from animals immunized with CFA alone, but much less than that seen with rats with experimental autoimmune glomerulonephritis, a model of antiglomerular basement membrane disease (Figure 3). Overall mean percentage of glomeruli with crescents in rats with EAV was 5.2% ± 1.6% (Figure 4). Consistent with the histologic findings, no immune deposits were evident on samples analyzed by electron microscopy (data not shown). All EAV rats, but no control rats, developed hematuria and 72% had albuminuria 6 weeks after immunization (> 1 mg/24 hours, mean 11.9 ± 4.4 mg/24 hour; Figure 4).

**Induction of ANCA in WKY rats augments leukocyte adhesion and transmigration induced by CXCL1**

Having demonstrated the presence of ANCA in our rat model of EAV, their effects on leukocyte-endothelial interaction in vivo were investigated by intravitral microscopy using the mesenteric preparation. For this purpose, leukocyte responses within rat mesenteric venules were observed and quantified in EAV rats in the absence of an inflammatory stimulus and after topical application of the...
chemokine CXCL1. CXCL1 is a rat homologue of IL-8, a chemokine which is likely to be of pathophysiologic relevance in ANCA-associated vasculitis.18 Intravital microscopy was performed on rats 6 to 7 weeks after immunization with hMPO or HSA. Of note, there was no significant difference between the 2 groups of rats with respect to multiple systemic or microhemodynamic parameters (Table 1). Furthermore, no significant difference in basal leukocyte rolling flux or leukocyte transmigration was noted between the 2 groups of rats. Baseline firm adhesion was variable and slightly higher in the HSA-immunized group as compared with the hMPO-immunized group. Although the reason for this small difference is unclear, overall the findings do not indicate the occurrence of increased leukocyte–vessel wall interactions in the EAV rats under basal conditions.

In contrast, after topical CXCL1 application, a significant increase in both leukocyte firm adhesion and transmigration was observed in hMPO-immunized compared with HSA-immunized rats (Figure 5). Sixty minutes after application of the chemokine, adhesion was increased by 32% in the hMPO-immunized group (P < .01), a response that was accompanied by a 65% increase in transmigration at 90 minutes (P < .001). There was no correlation between the severity of glomerular injury and the intravital microscopy findings. Thus, in an acute inflammatory milieu, as induced in the present study by local application of the chemokine CXCL1, hMPO-immunized rats, with high titers of circulating ANCAs, exhibited enhanced microvascular inflammatory responses of leukocyte adhesion and transmigration. These findings provide in vivo evidence of a potential pathophysiologic effect of ANCAs in EAV, a model with pathology that very closely mimics human ANCA-associated SVV.

Passive transfer of ANCA-rich Ig confers enhanced microvascular responses to CXCL1 in naive recipient rats

To confirm that the enhanced microvascular responses observed in rats with EAV were due to circulating ANCAs, Ig prepared from sera from hMPO- or HSA-immunized rats was transferred to naive WKY rats prior to quantification of leukocyte responses by intravital microscopy. The protocol used was similar to that described in the previous section, with the addition of a 30-minute quantification period following Ig injection prior to mesenteric superfusion with CXCL1 or Tyrode solution.

Injection of either EAV or control Ig (20 mg/kg) had no effect on baseline systemic or microhemodynamic variables (Table 1). Before Ig infusion, adhesion and transmigration levels were not significantly different between the 2 groups. However, following intravenous injection of EAV Ig, but not control Ig, leukocyte firm adhesion was significantly enhanced in rats treated with topical Tyrode solution (mean adhesion at 120 minutes after EAV and control Ig were 6.6 and 0.6 leukocytes/100 μm, respectively; n = 3-4; P < .001; Figure 6A). Interestingly, this increased adhesion response was not accompanied by an increase in leukocyte transmigration (Figure 6B). These results demonstrate that, using the present experimental protocol, ANCA-rich Ig on its own can induce leukocyte firm adhesion to venular walls, although this enhanced leukocyte-endothelial cell interaction does not lead to leukocyte transmigration. Hence, in light of our findings in the active immunization model, we next investigated the effect of intravenous ANCA-rich Ig on leukocyte responses induced by topical CXCL1. In agreement with our previous results, topical administration of this chemokine elicited time-dependent increases in both leukocyte firm adhesion and transmigration in rats
injected with control Ig, as compared with baseline values (Figure 6C–D). Both of these responses were enhanced in rats receiving ANCA-rich Ig, with the transmigration response at 90 minutes after application of CXCL1 being 79% greater in rats injected with EAV Ig, as compared with rats injected with control Ig.

Taken together, these findings demonstrate that the MPO-ANCAs induced in the EAV rat model of SVV have a biologic effect on leukocyte adhesion and transmigration in vivo. To address the association of ANCAs with vascular injury, the experimental models detailed in the previous two sections were extended to enable direct investigation of microvascular injury resulting in hemorrhage.

Transfer of ANCA can induce microvascular hemorrhage

Patients with SVV develop microvascular occlusion and destruction with consequent hemorrhage into surrounding tissue. This is manifested by purpura, lung hemorrhage, and bleeding into other organs. Hence, the effect of ANCAs on the hemorrhagic response to an inflammatory stimulus was of particular interest. To quantify
this variable by intravital microscopy, 2 methods were used, governed by the extent of the response. In actively immunized rats, where the hemorrhagic response was relatively extensive and focal sites of hemorrhage could be seen by naked eye (Figure 7A), or by histologic analysis (Figure 7B), the response was quantified as a fraction of responding venular segments. Using this approach, a trend toward an increase in hemorrhagic response following superfusion with CXCL1 was observed in hMPO-immunized rats (17.1%; interquartile range of 0-37 in EAV versus 0%; interquartile range of 0-15 in control rats; P = .09; Figure 7C). For quantification of minor degrees of hemorrhage, as observed in the passive transfer experiments, a global visual-analog score (0-5) was used to assess the severity of hemorrhage in the mesentery as a whole. Using this method, recipients of ANCA-rich Ig showed a significant increase in microvascular hemorrhagic response following topical application of CXCL1 (Figure 7D), with a trend toward spontaneous hemorrhage following superfusion with Tyrode solution alone. Real-time development of ANCA-induced microvascular hemorrhage is depicted in Video S1 (available at the Blood website; see the Supplemental Video link at the top of the online article).

Discussion

The presence of ANCs is implicated in the pathogenesis of SVV and has been shown in murine models to be sufficient to cause pauci-immune glomerulonephritis. However, to date, there has been no in vivo evidence directly associating these antibodies with leukocyte-mediated vascular damage. With the use of a novel rat model of ANCA-driven EAV, which has many similarities to human ANCA-associated vasculitis, our findings provide the first direct evidence for the ability of ANCs to enhance leukocyte–vessel wall interactions in vivo. Specifically, rats with EAV exhibited an exaggerated adhesion and transmigration response to a pathophysiologically relevant inflammatory stimulus, CXCL1, as observed by intravital microscopy. This effect was transferable to naive rats by transfer of Ig, proving that the effect was due to circulating ANCs. Indeed, ANCs on their own, without any additional topical stimulus, was capable of inducing firm adhesion of leukocytes to the vascular endothelium. Furthermore, our study provides evidence to support the concept that ANCA-induced exaggerated leukocyte responses can lead to vascular injury, as manifested by the development of microvascular hemorrhage. It is possible that these are early events in the cascade leading to necrotizing vasculitis.

WKY rats immunized with hMPO develop a polyclonal antibody response to this antigen that is accompanied by the development of pauci-immune focal necrotizing crescentic glomerulonephritis and pulmonary hemorrhage. This animal model of autoimmune SVV is similar in many respects to the analogous human disease and provides a unique opportunity to study the effects of ANCs in vivo. Specifically, the glomerular lesion seen, although relatively mild, is pauci-immune in nature, as demonstrated by immunofluorescence and electron microscopy; that is, there are only scant immune deposits present. The EAV model, like human AAV, is primarily a hemorrhagic disease. Although albuminuria is present in the majority of rats with EAV, it is mild (around 3-10 mg/24 hour) compared with other rat models of glomerulonephritis. This model has some similarities with previous work performed in the early 1990s. Brouwer et al used heterologous MPO (at a low dose, 10 μg/rat) to induce anti-MPO antibodies in Brown Norway rats. These animals developed granulomatous crescentic nephritis in kidneys perfused with lysosomal extract and hydrogen peroxide. Although immune deposits were initially felt to be transient in this model, Yang et al found deposits up to day 10. Although many researchers now feel that this is a model of immune-complex deposition disease, rather than pauci-immune vasculitis, it provided an important foundation for future work.

Although the protein sequences of rat (accession gi27674721) and human (accession gi4557759) MPO share 85.7% homology, previous studies using an ELISA-based approach have found that monoclonal anti-hMPO antibodies raised in mice, and sera from patients with AAV, have limited crossreactivity with rat MPO. Because of these reports, and because the binding of rat anti-hMPO antibodies to rat leukocytes was critical to our in vivo functional studies, initial experiments investigated this crossreactivity. Evidence was provided for the ability of anti-hMPO antibodies raised in rats to bind to rat leukocytes. We believe that the difference in views between the groups was due to the crossreactivity of the antibodies.
between our findings and those in the study by Patry et al\textsuperscript{23} relate to 2 factors. First, in the majority of their experiments, monoclonal antibodies were used, which presumably have activity against a restricted number of epitopes on the MPO molecule. We have induced high titers of polyclonal antibodies, among which there are apparently antibodies that crossreact with epitopes on the rat MPO molecule. Second, in the previous study, rat MPO was immobilized on plastic, which may alter the conformational epitopes compared with those found in the cellular systems that we used.

Leukocyte–vessel wall interactions in EAV rats, as compared with HSA-immunized control rats, were investigated in mesenteric venules as observed by intravital microscopy. Using this model, topical application of the chemokine CXCL1 induced a significant increase in leukocyte firm adhesion and transmigration in control rats, compared with rats treated with topical Tyrode solution. These responses were significantly enhanced in rats immunized with hMPO, resulting in a 65% increase in leukocyte transmigration in EAV rats 90 minutes after superfusion of the mesenteric tissue with CXCL1. Of note, CXCL1 is a rat homologue of the human chemokine IL-8 (CXCL8), an inflammatory mediator implicated in the pathogenesis of ANCA-associated vasculitis. The need for a priming factor to observe potentially pathogenic effects of ANCA on neutrophils is consistent with numerous previous in vitro studies. Priming with cytokines such as tumor necrosis factor α (TNFα) has been shown to be necessary to facilitate the stimulation by ANCs of enhanced neutrophil degranulation and neutrophil-dependent endothelial cytotoxicity. In addition, although the microvessels of the mesentery are not identical to those of the glomerular tuft, there is evidence to suggest that endothelial dysfunction seen in AASV is global.\textsuperscript{23} Thus, our findings demonstrate that the presence of ANCs have the capacity to enhance leukocyte–vessel wall interactions as induced by a pathologically relevant inflammatory mediator.

To assess directly the role of circulating ANCs in these observations, ANCA-rich Ig were prepared from the serum of EAV rats and administered to naive animals. Of note, it is not possible to compare directly the responses observed in these passive transfer experiments to those in the actively immunized animals, because the use of Freund adjuvant in the latter was associated with enhancement of all leukocyte-endothelial responses. Naïve rats injected intravenously with ANCA-rich Ig exhibited a rapid and significantly enhanced leukocyte firm adhesion response that was not observed in rats injected with control Ig. Interestingly, this increase in leukocyte firm adhesion was not associated with enhanced transmigration, suggesting that perhaps a second inflammatory stimulus was required to induce the migration of adherent leukocytes through venular walls. Indeed, topical application of CXCL1 to mesenteric tissue of rats previously injected with intravenous ANCA-rich Ig led to a significantly enhanced transmigration response, as compared with responses detected in naïve rats injected with Ig from HSA-immunized rats. Taken together, these findings provide the first direct evidence for the ability of ANCs

![Figure 5. Adhesion and transmigration profiles in WKY rats actively immunized with hMPO or HSA in response to topical CXCL1. Intravital microscopy was performed on rats 6 to 7 weeks after immunization with hMPO (EAV rats) or HSA (control rats). After recording baseline responses of adhesion (A) and transmigration (B), topical CXCL1 (3 × 10^{-9} M) or Tyrode balanced salt solution was superfused over the mesentery, and responses were quantified for a further 90 minutes, during which time superfusion of the topical agent was maintained. The data represent mean ± SEM, n = 11 to 13 separate rats per group for CXCL1 and n = 6 to 7 per group for Tyrode solution. Statistically significant differences between different groups of rats are shown by asterisks, *P < .05 and **P < .001.](image)

![Figure 6. Passive transfer of ANCA-rich immunoglobulin enhances microvascular responses in naïve WKY rats. Intravital microscopy was performed on naïve WKY rats following intravenous administration of 20 mg/kg pooled anti-hMPO-positive Ig (●) or control Ig (○), and leukocyte responses of adhesion (A,C) and transmigration (B,D) were measured for up to 2 hours. In some rats, after 30 minutes, the Tyrode mesenteric superfusion was changed to superfusion with 3 × 10^{-9} M CXCL1 (C,D), which was maintained for a further 90 minutes. The data represent the mean ± SEM, n = 5 separate rats in CXCL1 groups and n = 3 to 4 in Tyrode groups. Statistically significant differences between groups of rats are shown by asterisks, **P < .01, and ***P < .001.](image)
ANCAs to leukocytes has been shown to stimulate activation and/or up-regulation of β2 integrins. Indeed, as illustrated by Radford et al., under both static and flow conditions, ANCAs can markedly increase neutrophil adhesion to untreated and stimulated endothelium in a β2 integrin–dependent manner. Hence, we can speculate that, within the in vivo scenario of our studies, binding of ANCAs to neutrophils renders them primed for an enhanced adhesion response. In the presence of an inflammatory stimulus, such as CXCL1, these effects are then translated into greater levels of firm adhesion and subsequent transmigration. Based on the cited in vitro observations, many of these effects may be β2 integrin mediated, although the precise adhesive pathways involved in vivo are currently unknown and are under investigation in our laboratory.

As exaggerated leukocyte–vessel wall interactions can lead to leukocyte-mediated vascular damage, a characteristic feature of the pathology of SVV, we investigated the effect of ANCAs on vascular injury as manifested by local microvascular hemorrhage. For this purpose, to investigate ANCA-induced hemorrhage using intravital microscopy, 2 quantification procedures were established as governed by the extent of the responses observed. In both models, evidence was obtained for ANCA-induced microvascular hemorrhage, a response that was largely associated with ANCA-induced leukocyte transmigration. These findings are consistent with in vitro observations, indicating that ANCAs can induce degranulation of primed neutrophils, with consequent release of reactive oxygen species and proteolytic enzymes, responses that under conditions of neutrophil adhesion to endothelium could cause endothelial injury. Hence, our findings support the general hypothesis that ANCA-induced exaggerated leukocyte–vessel wall interactions can lead to vascular injury. This is in line with the recent description by Xiao et al. of the induction of SVV in mice by transfer of anti-MPO–rich antibodies.

Collectively, using a novel rat model of EAV, the present results provide the first direct evidence for the ability of ANCAs to induce leukocyte–vessel wall interactions and leukocyte-mediated vascular damage in vivo. We and others have recently defined the role of various treatment modalities for ANCA-associated vasculitis in the clinical arena, such as the duration of cyclophosphamide treatment, potential roles for anti-TNF biologic therapy, and the indications for antibody removal by plasma exchange. We now have the opportunity, using animal models, to design and test therapies targeting the specific pathways activated by ANCAs. This should lead to improved treatment for patients with SVV.

Acknowledgments

We thank Ms Jennifer Smith, Drs Alan Salama, Efrem Eren, Paul Cook, and Shijun Wang and Prof Patrick Maxwell for their advice.

References

7. Weidner S, Neupert W, Goppelt-Streube M, Rupprecht HD. Antineutrophil cytoplasmic antibodies